Long-acting broadly neutralizing anti–HIV-1 human IgG1 monoclonal antibody with LS Fc mutations for extended half-life; targets the gp120 CD4-binding site to neutralize virus and block entry, and engages Fcγ receptor–mediated effector functions (ADCC, phagocytosis) to eliminate Env-expressing infected cells and reduce the intact proviral reservoir.
Long-acting human IgG1 broadly neutralizing antibody (LS Fc half-life mutations) that binds the HIV-1 gp120 CD4-binding site to neutralize virions and block entry into CD4+ T cells; engages Fcγ receptors to mediate ADCC and phagocytosis of Env-expressing infected cells, aiming to reduce the intact proviral reservoir.
NO
INDIRECT
3BNC117-LS binds HIV-1 gp120 on infected cells; its Fc engages Fcγ receptors (including CD32a) on effector cells to trigger ADCC/phagocytosis of Env+ targets. CD32a-expressing cells serve as effectors, not killed targets.
Long-acting broadly neutralizing anti–HIV-1 human IgG1 monoclonal antibody with LS Fc mutations for extended half-life; targets the gp120 V3 glycan (N332) supersite to neutralize virus and block entry, and engages Fcγ receptor–mediated effector functions (ADCC, phagocytosis) to eliminate Env-expressing infected cells and reduce the intact proviral reservoir.
A long-acting broadly neutralizing human IgG1 monoclonal antibody with LS Fc mutations that extend half-life; it binds the HIV-1 Env gp120 V3 glycan (N332) supersite to neutralize virions and block viral entry, and engages Fcγ receptors to mediate ADCC and phagocytosis of Env-expressing infected cells, aiming to reduce the intact proviral reservoir.
YES
DIRECT
The antibody binds the gp120 V3 N332 supersite on Env displayed by infected cells and engages Fcγ receptors on NK cells/macrophages to trigger ADCC and antibody-dependent phagocytosis, leading to killing/removal of the target cells.
An intravenous antibody–drug conjugate (ADC) composed of an anti–Nectin-4 monoclonal antibody that binds Nectin-4 (PVRL4) on tumor cells, is internalized, and releases an intracellular cytotoxic payload to kill Nectin-4–expressing cells, with potential bystander effect.
LY4101174 is an intravenous anti–Nectin-4 IgG1 antibody–drug conjugate that binds Nectin-4 (PVRL4) on tumor cells, is internalized, and releases the topoisomerase I inhibitor exatecan via a cleavable linker, causing inhibition of DNA replication, cell‑cycle arrest, and apoptosis of Nectin‑4–expressing cells, with potential bystander effect.
NO
INDIRECT
The ADC binds Nectin-4 on tumor cells, is internalized, and releases exatecan, which inhibits DNA topoisomerase I to cause DNA replication arrest and apoptosis. Topoisomerase I is the intracellular payload target, not the cell-surface antigen used for targeting.
Long-acting broadly neutralizing anti–HIV-1 human IgG1 monoclonal antibody with LS Fc mutations for extended half-life; targets the gp120 V3 glycan (N332) supersite to neutralize virus and block entry, and engages Fcγ receptor–mediated effector functions (ADCC, phagocytosis) to eliminate Env-expressing infected cells and reduce the intact proviral reservoir.
A long-acting broadly neutralizing human IgG1 monoclonal antibody with LS Fc mutations that extend half-life; it binds the HIV-1 Env gp120 V3 glycan (N332) supersite to neutralize virions and block viral entry, and engages Fcγ receptors to mediate ADCC and phagocytosis of Env-expressing infected cells, aiming to reduce the intact proviral reservoir.
NO
INDIRECT
10-1074-LS binds FcRn only to extend antibody half-life via recycling; it does not target or kill FcRn-expressing cells. Any killing by this drug is via Fcγ receptor–mediated ADCC/phagocytosis against HIV Env–expressing infected cells, not FcRn+ cells.
Long-acting broadly neutralizing anti–HIV-1 human IgG1 monoclonal antibody with LS Fc mutations for extended half-life; targets the gp120 V3 glycan (N332) supersite to neutralize virus and block entry, and engages Fcγ receptor–mediated effector functions (ADCC, phagocytosis) to eliminate Env-expressing infected cells and reduce the intact proviral reservoir.
A long-acting broadly neutralizing human IgG1 monoclonal antibody with LS Fc mutations that extend half-life; it binds the HIV-1 Env gp120 V3 glycan (N332) supersite to neutralize virions and block viral entry, and engages Fcγ receptors to mediate ADCC and phagocytosis of Env-expressing infected cells, aiming to reduce the intact proviral reservoir.
NO
INDIRECT
The IgG1 binds HIV-1 Env on infected cells via Fab and engages CD16a on NK cells via Fc to trigger ADCC/phagocytosis, killing Env+ targets; CD16a-expressing cells are effectors, not killed.